Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.60 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
| ▸ | PAFAH1B2 | P68402 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193738 | 1.00 | LPAR3 (0.60) | LPAR3LPAR2LPAR1CYP3A4GGPS1 | |
| SCHEMBL193525 | 0.95 | LPAR3 (0.57) | LPAR3LPAR2LPAR1CYP3A4GGPS1 | |
| SCHEMBL193526 | 0.95 | LPAR3 (0.57) | LPAR3LPAR2LPAR1CYP3A4GGPS1 | |
| SCHEMBL194046 | 0.92 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4GGPS1 | |
| SCHEMBL194047 | 0.92 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4GGPS1 | |
| SCHEMBL194232 | 0.85 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4MEN1 | |
| SCHEMBL193122 | 0.85 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4MEN1 | |
| SCHEMBL194233 | 0.85 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4MEN1 | |
| SCHEMBL193121 | 0.85 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CYP3A4MEN1 | |
| SCHEMBL27577557 | 0.84 | CYP3A4 (0.56) | LPAR3LPAR2LPAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481743-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUND (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2433946-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUNDATION (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2767541-A1 | LPA receptor agonists and antagonists | Rxbio, Inc. (US) | 2014-08-20 | — | — | EP | disclosed |
| EP-2262371-B1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS | RXBIO INC (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2481743-A1 | LPA receptor agonists and antagonists and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120135967-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | MILLER DUANE D (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2433946-A1 | LPA receptor agonists and antagonists and methods of use | University of Tennessee Research Foundation (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120010424-A1 | LPA Receptor Agonists and Antagonists | RXBIO INC. | 2012-01-12 | — | — | US | disclosed |
| EP-1678096-B1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES FOUNDATION (US) | 2012-01-04 | — | — | EP | disclosed |
| US-7947665-B2 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | MILLER DUANE D | 2011-05-24 | — | — | US | disclosed |
| EP-2262371-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS | Rxbio, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010051053-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS | RXBIO, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20080090783-A1 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | MILLER DUANE D | 2008-04-17 | — | — | US | disclosed |
| US-7217704-B2 | LPA receptor agonists and antagonists and methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1678096-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1678096-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-01-12 | — | — | US | disclosed |
| WO-2005032494-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | LPAR1, LPAR6, LPAR2 | LPAR3 6/4885LPAR2 3/4885LPAR1 1/4885 |
| US-20120010424-A1 | LPA Receptor Agonists and Antagonists | LPAR1, LPAR2, LPAR4 | LPAR3 4/4885LPAR2 2/4885LPAR1 1/4885 |
| US-20120135967-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | LPAR1, LPAR2, LPAR4 | LPAR3 5/4885LPAR2 2/4885LPAR1 1/4885 |
| US-20080090783-A1 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | LPAR1, LPAR4, LPAR2 | LPAR3 6/4885LPAR2 3/4885LPAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.